Compare ALEMBIC LTD with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC LTD vs STRIDES PHARMA SCIENCE - Comparison Results

ALEMBIC LTD     Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC LTD STRIDES PHARMA SCIENCE ALEMBIC LTD/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 73.7 14.8 498.1% View Chart
P/BV x 2.6 0.9 299.4% View Chart
Dividend Yield % 0.4 0.6 70.1%  

Financials

 ALEMBIC LTD   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    ALEMBIC LTD
Mar-18
STRIDES PHARMA SCIENCE
Mar-18
ALEMBIC LTD/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs721,147 6.3%   
Low Rs34642 5.3%   
Sales per share (Unadj.) Rs4.7317.2 1.5%  
Earnings per share (Unadj.) Rs6.17.8 77.8%  
Cash flow per share (Unadj.) Rs6.225.1 24.9%  
Dividends per share (Unadj.) Rs0.202.00 10.0%  
Dividend yield (eoy) %0.40.2 168.9%  
Book value per share (Unadj.) Rs40.7274.3 14.8%  
Shares outstanding (eoy) m267.0389.50 298.4%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x11.32.8 399.5%   
Avg P/E ratio x8.7114.0 7.6%  
P/CF ratio (eoy) x8.535.7 23.7%  
Price / Book Value ratio x1.33.3 39.9%  
Dividend payout %3.325.5 12.9%   
Avg Mkt Cap Rs m14,13980,058 17.7%   
No. of employees `000NA2.5 0.0%   
Total wages/salary Rs m2074,341 4.8%   
Avg. sales/employee Rs ThNM11,325.8-  
Avg. wages/employee Rs ThNM1,731.4-  
Avg. net profit/employee Rs ThNM280.1-  
INCOME DATA
Net Sales Rs m1,25528,394 4.4%  
Other income Rs m370941 39.4%   
Total revenues Rs m1,62529,334 5.5%   
Gross profit Rs m1113,965 2.8%  
Depreciation Rs m381,540 2.5%   
Interest Rs m21,962 0.1%   
Profit before tax Rs m4421,403 31.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m1,212-168 -721.4%   
Extraordinary Inc (Exp) Rs m0-436 0.0%   
Tax Rs m2497 24.6%   
Profit after tax Rs m1,630702 232.1%  
Gross profit margin %8.914.0 63.4%  
Effective tax rate %5.46.9 78.2%   
Net profit margin %129.82.5 5,251.2%  
BALANCE SHEET DATA
Current assets Rs m1,86724,836 7.5%   
Current liabilities Rs m59118,993 3.1%   
Net working cap to sales %101.620.6 494.0%  
Current ratio x3.21.3 241.5%  
Inventory Days Days9471 132.8%  
Debtors Days Days74113 64.8%  
Net fixed assets Rs m1,79134,289 5.2%   
Share capital Rs m534895 59.7%   
"Free" reserves Rs m10,32423,651 43.7%   
Net worth Rs m10,85824,546 44.2%   
Long term debt Rs m4115,513 0.3%   
Total assets Rs m11,59165,437 17.7%  
Interest coverage x260.91.7 15,211.4%   
Debt to equity ratio x00.6 0.6%  
Sales to assets ratio x0.10.4 25.0%   
Return on assets %14.14.1 345.7%  
Return on equity %15.02.9 524.8%  
Return on capital %15.26.9 220.3%  
Exports to sales %1.50-   
Imports to sales %21.00-   
Exports (fob) Rs m19NA-   
Imports (cif) Rs m263NA-   
Fx inflow Rs m1915,697 0.1%   
Fx outflow Rs m264735 35.9%   
Net fx Rs m-24414,962 -1.6%   
CASH FLOW
From Operations Rs m2361,871 12.6%  
From Investments Rs m-2245,826 -3.8%  
From Financial Activity Rs m-27-10,157 0.3%  
Net Cashflow Rs m-15-2,615 0.6%  

Share Holding

Indian Promoters % 64.0 27.7 231.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 37.8 0.5%  
FIIs % 9.7 8.6 112.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.1 25.9 100.8%  
Shareholders   54,701 56,241 97.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC LTD With:   IPCA LABS  NOVARTIS  ALEMBIC PHARMA  PROCTER & GAMBLE HEALTH  SANOFI INDIA  

Compare ALEMBIC LTD With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

ALEMBIC LTD Announces Quarterly Results (1QFY20); Net Profit Down 70.9% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

ALEMBIC LTD Announces Quarterly Results (4QFY19); Net Profit Down 14.6% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, ALEMBIC LTD has posted a net profit of Rs 40 m (down 14.6% YoY). Sales on the other hand came in at Rs 253 m (down 23.8% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

ALEMBIC LTD Announces Quarterly Results (3QFY19); Net Profit Down 41.9% (Quarterly Result Update)

Feb 1, 2019 | Updated on Feb 1, 2019

For the quarter ended December 2018, ALEMBIC LTD has posted a net profit of Rs 32 m (down 41.9% YoY). Sales on the other hand came in at Rs 243 m (down 18.8% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC LTD SHARE PRICE


Sep 20, 2019 (Close)

TRACK ALEMBIC LTD

  • Track your investment in ALEMBIC LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ALEMBIC LTD - STRIDES PHARMA SCIENCE COMPARISON

COMPARE ALEMBIC LTD WITH

MARKET STATS